Ramixole

Class: Central Nervous System
Dosage Form: Tablets
Description: Dopamine agonist anti-parkinsonian agent
Stock: Available
Manufacturer: Eva Pharma

Composition:

Pramipexole dihydrochloride monohydrate…………..0.25 or 1 mg

Properties:

Pramipexole dihydrochloride – a benzothiazolamine derivative – is a non-ergot dopamine receptor agonist. Its action is through mimicking brain activities of a PD patient who would otherwise normally respond to dopamine. Pramipexole may be used with or without levodopa and has been shown to be effective in delaying the development of levodopa-associated motor fluctuations and dyskinesias

Indications:

For treatment of signs and symptoms associated with idiopathic Parkinson’s disease. It can be used alone or in combination with other therapies and it is effective in treating both early and advanced stages of the disease.

Contraindicatons:

Ramixole is contraindicated in case of hypersensitivity to any of the product ingredients.

Drug Interactions:

The following interactions are to be noted:

  • When combined with levodopa/carbidopa  pramipexole caused an earlier Tmax for levodopa but resulted in no changes in the extent of levodopa absorption or elimination
  • Avoid concomitant use of antipsychotic
  • Excretion of pramipexole reduced by cimetidine
  • Effects of dopaminergics possibly enhanced by memantine

Side Effects:

Nausea, insomnia, asthenia, constipation, drowsiness and hallucinations.

Dosage and Administration:

Initial dose is 0.125 mg of Pramipexole dihydrochloride monohydrate to be repeated three times daily, the dose is increased to 0.25 mg three times daily within 5 to 7 days. The dose may be increased by 0.75 mg at weekly intervals up to a maximum dose of 4.5 mg per day. Ramixole may be taken with or without food and should not be discontinued abruptly.

Warnings:

Dosage reduction should be adjusted by physician in renal and hepatic impairment, in psychotic disorders, in severe cardiovascular diseases and in pregnancy.
Caution should be exerted in patients who experience symptoms of sleepiness and somnolence when driving or operating machinery.

Packaging:

Boxes of one or two blisters each containing 10 tablets.

Storage:

Store at room temperature, below 25°C.

No Comments

Leave a Reply

%d bloggers like this:
Skip to toolbar